Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 18 entries
Sorted by: Best Match Show Resources per page
Locked-in syndrome after basilary artery thrombosis by mucormycosis masquerading as meningoencephalitis in a lymphoma patient.

Ecancermedicalscience

Maffini F, Cocorocchio E, Pruneri G, Bonomo G, Peccatori F, Chiapparini L, Vincenzo SD, Martinelli G, Viale G.
PMID: 24386011
Ecancermedicalscience. 2013 Dec 19;7:382. doi: 10.3332/ecancer.2013.382. eCollection 2013.

Locked-in syndrome is a rare clinical syndrome due to basilary artery thrombosis generally associated with trauma, vascular, or cardiac malformation. It can present as various types of clinical evolution and occasionally masquerades as other pathological conditions, such as infective...

Cite
Maffini F, Cocorocchio E, Pruneri G, et al. Locked-in syndrome after basilary artery thrombosis by mucormycosis masquerading as meningoencephalitis in a lymphoma patient. Ecancermedicalscience. 2013;7:382doi: 10.3332/ecancer.2013.382.
Maffini, F., Cocorocchio, E., Pruneri, G., Bonomo, G., Peccatori, F., Chiapparini, L., Vincenzo, S. D., Martinelli, G., & Viale, G. (2013). Locked-in syndrome after basilary artery thrombosis by mucormycosis masquerading as meningoencephalitis in a lymphoma patient. Ecancermedicalscience, 7382. https://doi.org/10.3332/ecancer.2013.382
Maffini, Fausto, et al. "Locked-in syndrome after basilary artery thrombosis by mucormycosis masquerading as meningoencephalitis in a lymphoma patient." Ecancermedicalscience vol. 7 (2013): 382. doi: https://doi.org/10.3332/ecancer.2013.382
Maffini F, Cocorocchio E, Pruneri G, Bonomo G, Peccatori F, Chiapparini L, Vincenzo SD, Martinelli G, Viale G. Locked-in syndrome after basilary artery thrombosis by mucormycosis masquerading as meningoencephalitis in a lymphoma patient. Ecancermedicalscience. 2013 Dec 19;7:382. doi: 10.3332/ecancer.2013.382. eCollection 2013. PMID: 24386011; PMCID: PMC3869474.
Copy Download .nbib Format: NLM
Novel Biomarkers and Druggable Targets in Advanced Melanoma.

Cancers

Ferrucci PF, Cocorocchio E.
PMID: 35008245
Cancers (Basel). 2021 Dec 24;14(1). doi: 10.3390/cancers14010081.

Immunotherapy with Ipilimumab or antibodies against programmed death (ligand) 1 (anti-PD1/PDL1), targeted therapies with BRAF-inhibitors (anti-BRAF) and their combinations significantly changed melanoma treatment options in both primary, adjuvant and metastatic setting, allowing for a cure, or at least long-term...

Cite
Ferrucci PF, Cocorocchio E. Novel Biomarkers and Druggable Targets in Advanced Melanoma. Cancers (Basel). 2021;14(1)doi: 10.3390/cancers14010081.
Ferrucci, P. F., & Cocorocchio, E. (2021). Novel Biomarkers and Druggable Targets in Advanced Melanoma. Cancers, 14(1), . https://doi.org/10.3390/cancers14010081
Ferrucci, Pier Francesco, and Cocorocchio, Emilia. "Novel Biomarkers and Druggable Targets in Advanced Melanoma." Cancers vol. 14,1 (2021). doi: https://doi.org/10.3390/cancers14010081
Ferrucci PF, Cocorocchio E. Novel Biomarkers and Druggable Targets in Advanced Melanoma. Cancers (Basel). 2021 Dec 24;14(1). doi: 10.3390/cancers14010081. PMID: 35008245.
Copy Download .nbib Format: NLM
Talimogene Laherparepvec (T-VEC): An Intralesional Cancer Immunotherapy for Advanced Melanoma.

Cancers

Ferrucci PF, Pala L, Conforti F, Cocorocchio E.
PMID: 33803762
Cancers (Basel). 2021 Mar 18;13(6). doi: 10.3390/cancers13061383.

Direct intralesional injection of specific or even generic agents, has been proposed over the years as cancer immunotherapy, in order to treat cutaneous or subcutaneous metastasis. Such treatments usually induce an effective control of disease in injected lesions, but...

Cite
Ferrucci PF, Pala L, Conforti F, et al. Talimogene Laherparepvec (T-VEC): An Intralesional Cancer Immunotherapy for Advanced Melanoma. Cancers (Basel). 2021;13(6)doi: 10.3390/cancers13061383.
Ferrucci, P. F., Pala, L., Conforti, F., & Cocorocchio, E. (2021). Talimogene Laherparepvec (T-VEC): An Intralesional Cancer Immunotherapy for Advanced Melanoma. Cancers, 13(6), . https://doi.org/10.3390/cancers13061383
Ferrucci, Pier Francesco, et al. "Talimogene Laherparepvec (T-VEC): An Intralesional Cancer Immunotherapy for Advanced Melanoma." Cancers vol. 13,6 (2021). doi: https://doi.org/10.3390/cancers13061383
Ferrucci PF, Pala L, Conforti F, Cocorocchio E. Talimogene Laherparepvec (T-VEC): An Intralesional Cancer Immunotherapy for Advanced Melanoma. Cancers (Basel). 2021 Mar 18;13(6). doi: 10.3390/cancers13061383. PMID: 33803762; PMCID: PMC8003308.
Copy Download .nbib Format: NLM
Baseline relative eosinophil count as a predictive biomarker for ipilimumab treatment in advanced melanoma.

Oncotarget

Ferrucci PF, Gandini S, Cocorocchio E, Pala L, Baldini F, Mosconi M, Antonini Cappellini GC, Albertazzi E, Martinoli C.
PMID: 29108362
Oncotarget. 2017 Aug 01;8(45):79809-79815. doi: 10.18632/oncotarget.19748. eCollection 2017 Oct 03.

As diverse therapeutic options are now available for advanced melanoma patients, predictive markers that may assist treatment decision are needed. A model based on baseline serum lactate dehydrogenase (LDH), peripheral blood relative lymphocyte counts (RLC) and eosinophil counts (REC)...

Cite
Ferrucci PF, Gandini S, Cocorocchio E, et al. Baseline relative eosinophil count as a predictive biomarker for ipilimumab treatment in advanced melanoma. Oncotarget. 2017;8(45):79809-79815doi: 10.18632/oncotarget.19748.
Ferrucci, P. F., Gandini, S., Cocorocchio, E., Pala, L., Baldini, F., Mosconi, M., Antonini Cappellini, G. C., Albertazzi, E., & Martinoli, C. (2017). Baseline relative eosinophil count as a predictive biomarker for ipilimumab treatment in advanced melanoma. Oncotarget, 8(45), 79809-79815. https://doi.org/10.18632/oncotarget.19748
Ferrucci, Pier Francesco, et al. "Baseline relative eosinophil count as a predictive biomarker for ipilimumab treatment in advanced melanoma." Oncotarget vol. 8,45 (2017): 79809-79815. doi: https://doi.org/10.18632/oncotarget.19748
Ferrucci PF, Gandini S, Cocorocchio E, Pala L, Baldini F, Mosconi M, Antonini Cappellini GC, Albertazzi E, Martinoli C. Baseline relative eosinophil count as a predictive biomarker for ipilimumab treatment in advanced melanoma. Oncotarget. 2017 Aug 01;8(45):79809-79815. doi: 10.18632/oncotarget.19748. eCollection 2017 Oct 03. PMID: 29108362; PMCID: PMC5668095.
Copy Download .nbib Format: NLM
Intensified ChlVPP/ABVVP chemotherapy regimen and pegfilgrastim support in advanced Hodgkin lymphoma.

Ecancermedicalscience

Cocorocchio E, Vanazzi A, Bassi S, Peccatori F, Antoniotti P, Gigli F, Travaini L, Piperno G, Pruneri G, Preda L, Biffi R, Botteri E, Negri M, Martinelli G.
PMID: 22276036
Ecancermedicalscience. 2010;4:184. doi: 10.3332/ecancer.2010.184. Epub 2010 Sep 08.

We present feasibility, toxicity and efficacy results of an intensified six-cycle ChlVPP/ABVVP regimen in advanced Hodgkin lymphoma (HL). From February 2004 to August 2007, 82 consecutive eligible patients were enrolled. According to the Hasenclever index, 64 patients (78%) were...

Cite
Cocorocchio E, Vanazzi A, Bassi S, et al. Intensified ChlVPP/ABVVP chemotherapy regimen and pegfilgrastim support in advanced Hodgkin lymphoma. Ecancermedicalscience. 2010;4:184doi: 10.3332/ecancer.2010.184.
Cocorocchio, E., Vanazzi, A., Bassi, S., Peccatori, F., Antoniotti, P., Gigli, F., Travaini, L., Piperno, G., Pruneri, G., Preda, L., Biffi, R., Botteri, E., Negri, M., & Martinelli, G. (2010). Intensified ChlVPP/ABVVP chemotherapy regimen and pegfilgrastim support in advanced Hodgkin lymphoma. Ecancermedicalscience, 4184. https://doi.org/10.3332/ecancer.2010.184
Cocorocchio, E, et al. "Intensified ChlVPP/ABVVP chemotherapy regimen and pegfilgrastim support in advanced Hodgkin lymphoma." Ecancermedicalscience vol. 4 (2010): 184. doi: https://doi.org/10.3332/ecancer.2010.184
Cocorocchio E, Vanazzi A, Bassi S, Peccatori F, Antoniotti P, Gigli F, Travaini L, Piperno G, Pruneri G, Preda L, Biffi R, Botteri E, Negri M, Martinelli G. Intensified ChlVPP/ABVVP chemotherapy regimen and pegfilgrastim support in advanced Hodgkin lymphoma. Ecancermedicalscience. 2010;4:184. doi: 10.3332/ecancer.2010.184. Epub 2010 Sep 08. PMID: 22276036; PMCID: PMC3234024.
Copy Download .nbib Format: NLM
Sex-Based Dimorphism of Anticancer Immune Response and Molecular Mechanisms of Immune Evasion.

Clinical cancer research : an official journal of the American Association for Cancer Research

Conforti F, Pala L, Pagan E, Bagnardi V, De Pas T, Queirolo P, Pennacchioli E, Catania C, Cocorocchio E, Ferrucci PF, Saponara M, Orsolini G, Zagami P, Nicoló E, De Marinis F, Tortora G, Bria E, Minucci S, Joffe H, Veronesi P, Wargo J, Rosenthal R, Swanton C, Mantovani A, Gelber RD, Viale G, Goldhirsch A, Giaccone G.
PMID: 34016641
Clin Cancer Res. 2021 Aug 01;27(15):4311-4324. doi: 10.1158/1078-0432.CCR-21-0136. Epub 2021 May 20.

PURPOSE: We previously demonstrated that sex influences response to immune checkpoint inhibitors. In this article, we investigate sex-based differences in the molecular mechanisms of anticancer immune response and immune evasion in patients with NSCLC.EXPERIMENTAL DESIGN: We analyzed (i) transcriptome...

Cite
Conforti F, Pala L, Pagan E, et al. Sex-Based Dimorphism of Anticancer Immune Response and Molecular Mechanisms of Immune Evasion. Clin Cancer Res. 2021;27(15):4311-4324doi: 10.1158/1078-0432.CCR-21-0136.
Conforti, F., Pala, L., Pagan, E., Bagnardi, V., De Pas, T., Queirolo, P., Pennacchioli, E., Catania, C., Cocorocchio, E., Ferrucci, P. F., Saponara, M., Orsolini, G., Zagami, P., Nicoló, E., De Marinis, F., Tortora, G., Bria, E., Minucci, S., Joffe, H., Veronesi, P., Wargo, J., Rosenthal, R., Swanton, C., Mantovani, A., Gelber, R. D., Viale, G., Goldhirsch, A., & Giaccone, G. (2021). Sex-Based Dimorphism of Anticancer Immune Response and Molecular Mechanisms of Immune Evasion. Clinical cancer research : an official journal of the American Association for Cancer Research, 27(15), 4311-4324. https://doi.org/10.1158/1078-0432.CCR-21-0136
Conforti, Fabio, et al. "Sex-Based Dimorphism of Anticancer Immune Response and Molecular Mechanisms of Immune Evasion." Clinical cancer research : an official journal of the American Association for Cancer Research vol. 27,15 (2021): 4311-4324. doi: https://doi.org/10.1158/1078-0432.CCR-21-0136
Conforti F, Pala L, Pagan E, Bagnardi V, De Pas T, Queirolo P, Pennacchioli E, Catania C, Cocorocchio E, Ferrucci PF, Saponara M, Orsolini G, Zagami P, Nicoló E, De Marinis F, Tortora G, Bria E, Minucci S, Joffe H, Veronesi P, Wargo J, Rosenthal R, Swanton C, Mantovani A, Gelber RD, Viale G, Goldhirsch A, Giaccone G. Sex-Based Dimorphism of Anticancer Immune Response and Molecular Mechanisms of Immune Evasion. Clin Cancer Res. 2021 Aug 01;27(15):4311-4324. doi: 10.1158/1078-0432.CCR-21-0136. Epub 2021 May 20. PMID: 34016641; PMCID: PMC7611463.
Copy Download .nbib Format: NLM
Successful treatment with avapritinib in patient with mucosal metastatic melanoma.

Therapeutic advances in medical oncology

Cocorocchio E, Pala L, Conforti F, Guerini-Rocco E, De Pas T, Ferrucci PF.
PMID: 32821296
Ther Adv Med Oncol. 2020 Jul 31;12:1758835920946158. doi: 10.1177/1758835920946158. eCollection 2020.

Metastatic vulvar melanoma is a rare and aggressive disease and survival is usually poor. Vulvar melanomas harbor BRAF V600 mutations only infrequently; consequently, target therapy is a rare therapeutic option and immunotherapy usually has only a weak effect. On...

Cite
Cocorocchio E, Pala L, Conforti F, et al. Successful treatment with avapritinib in patient with mucosal metastatic melanoma. Ther Adv Med Oncol. 2020;12:1758835920946158doi: 10.1177/1758835920946158.
Cocorocchio, E., Pala, L., Conforti, F., Guerini-Rocco, E., De Pas, T., & Ferrucci, P. F. (2020). Successful treatment with avapritinib in patient with mucosal metastatic melanoma. Therapeutic advances in medical oncology, 121758835920946158. https://doi.org/10.1177/1758835920946158
Cocorocchio, Emilia, et al. "Successful treatment with avapritinib in patient with mucosal metastatic melanoma." Therapeutic advances in medical oncology vol. 12 (2020): 1758835920946158. doi: https://doi.org/10.1177/1758835920946158
Cocorocchio E, Pala L, Conforti F, Guerini-Rocco E, De Pas T, Ferrucci PF. Successful treatment with avapritinib in patient with mucosal metastatic melanoma. Ther Adv Med Oncol. 2020 Jul 31;12:1758835920946158. doi: 10.1177/1758835920946158. eCollection 2020. PMID: 32821296; PMCID: PMC7406922.
Copy Download .nbib Format: NLM
Corrigendum: Association of CTLA-4 Gene Variants with Response to Therapy and Long-term Survival in Metastatic Melanoma Patients Treated with Ipilimumab: An Italian Melanoma Intergroup Study.

Frontiers in immunology

Queirolo P, Dozin B, Morabito A, Banelli B, Piccioli P, Fava C, Leo C, Carosio R, Laurent S, Fontana V, Ferrucci PF, Martinoli C, Cocorocchio E, Battaglia A, Ascierto PA, Capone M, Simeone E, De Galitiis F, Pagani E, Antonini Cappellini GC, Marchetti P, Guida M, Tommasi S, Mandalà M, Merelli B, Quaglino P, Fava P, Guidoboni M, Romani M, Spagnolo F, Pistillo MP.
PMID: 29531523
Front Immunol. 2018 Mar 02;9:403. doi: 10.3389/fimmu.2018.00403. eCollection 2018.

[This corrects the article on p. 386 in vol. 8, PMID: 28446908.].

Cite
Queirolo P, Dozin B, Morabito A, et al. Corrigendum: Association of CTLA-4 Gene Variants with Response to Therapy and Long-term Survival in Metastatic Melanoma Patients Treated with Ipilimumab: An Italian Melanoma Intergroup Study. Front Immunol. 2018;9:403doi: 10.3389/fimmu.2018.00403.
Queirolo, P., Dozin, B., Morabito, A., Banelli, B., Piccioli, P., Fava, C., Leo, C., Carosio, R., Laurent, S., Fontana, V., Ferrucci, P. F., Martinoli, C., Cocorocchio, E., Battaglia, A., Ascierto, P. A., Capone, M., Simeone, E., De Galitiis, F., Pagani, E., Antonini Cappellini, G. C., Marchetti, P., Guida, M., Tommasi, S., Mandalà, M., Merelli, B., Quaglino, P., Fava, P., Guidoboni, M., Romani, M., Spagnolo, F., & Pistillo, M. P. (2018). Corrigendum: Association of CTLA-4 Gene Variants with Response to Therapy and Long-term Survival in Metastatic Melanoma Patients Treated with Ipilimumab: An Italian Melanoma Intergroup Study. Frontiers in immunology, 9403. https://doi.org/10.3389/fimmu.2018.00403
Queirolo, Paola, et al. "Corrigendum: Association of CTLA-4 Gene Variants with Response to Therapy and Long-term Survival in Metastatic Melanoma Patients Treated with Ipilimumab: An Italian Melanoma Intergroup Study." Frontiers in immunology vol. 9 (2018): 403. doi: https://doi.org/10.3389/fimmu.2018.00403
Queirolo P, Dozin B, Morabito A, Banelli B, Piccioli P, Fava C, Leo C, Carosio R, Laurent S, Fontana V, Ferrucci PF, Martinoli C, Cocorocchio E, Battaglia A, Ascierto PA, Capone M, Simeone E, De Galitiis F, Pagani E, Antonini Cappellini GC, Marchetti P, Guida M, Tommasi S, Mandalà M, Merelli B, Quaglino P, Fava P, Guidoboni M, Romani M, Spagnolo F, Pistillo MP. Corrigendum: Association of CTLA-4 Gene Variants with Response to Therapy and Long-term Survival in Metastatic Melanoma Patients Treated with Ipilimumab: An Italian Melanoma Intergroup Study. Front Immunol. 2018 Mar 02;9:403. doi: 10.3389/fimmu.2018.00403. eCollection 2018. PMID: 29531523; PMCID: PMC5840259.
Copy Download .nbib Format: NLM
Vitamin D and the Risk of Non-Melanoma Skin Cancer: A Systematic Literature Review and Meta-Analysis on Behalf of the Italian Melanoma Intergroup.

Cancers

Caini S, Gnagnarella P, Stanganelli I, Bellerba F, Cocorocchio E, Queirolo P, Bendinelli B, Saieva C, Raimondi S, Gandini S.
PMID: 34638299
Cancers (Basel). 2021 Sep 26;13(19). doi: 10.3390/cancers13194815.

We aimed to provide a comprehensive overview of the link between vitamin D and non-melanoma skin cancer (NMSC). For this purpose, we conducted a systematic literature review (updated to 3 February 2021) and meta-analysis of the studies reporting on...

Cite
Caini S, Gnagnarella P, Stanganelli I, et al. Vitamin D and the Risk of Non-Melanoma Skin Cancer: A Systematic Literature Review and Meta-Analysis on Behalf of the Italian Melanoma Intergroup. Cancers (Basel). 2021;13(19)doi: 10.3390/cancers13194815.
Caini, S., Gnagnarella, P., Stanganelli, I., Bellerba, F., Cocorocchio, E., Queirolo, P., Bendinelli, B., Saieva, C., Raimondi, S., & Gandini, S. (2021). Vitamin D and the Risk of Non-Melanoma Skin Cancer: A Systematic Literature Review and Meta-Analysis on Behalf of the Italian Melanoma Intergroup. Cancers, 13(19), . https://doi.org/10.3390/cancers13194815
Caini, Saverio, et al. "Vitamin D and the Risk of Non-Melanoma Skin Cancer: A Systematic Literature Review and Meta-Analysis on Behalf of the Italian Melanoma Intergroup." Cancers vol. 13,19 (2021). doi: https://doi.org/10.3390/cancers13194815
Caini S, Gnagnarella P, Stanganelli I, Bellerba F, Cocorocchio E, Queirolo P, Bendinelli B, Saieva C, Raimondi S, Gandini S. Vitamin D and the Risk of Non-Melanoma Skin Cancer: A Systematic Literature Review and Meta-Analysis on Behalf of the Italian Melanoma Intergroup. Cancers (Basel). 2021 Sep 26;13(19). doi: 10.3390/cancers13194815. PMID: 34638299; PMCID: PMC8508211.
Copy Download .nbib Format: NLM
Novel Biomarkers and Druggable Targets in Advanced Melanoma.

Cancers

Ferrucci PF, Cocorocchio E.
PMID: 35008245
Cancers (Basel). 2021 Dec 24;14(1). doi: 10.3390/cancers14010081.

Immunotherapy with Ipilimumab or antibodies against programmed death (ligand) 1 (anti-PD1/PDL1), targeted therapies with BRAF-inhibitors (anti-BRAF) and their combinations significantly changed melanoma treatment options in both primary, adjuvant and metastatic setting, allowing for a cure, or at least long-term...

Cite
Ferrucci PF, Cocorocchio E. Novel Biomarkers and Druggable Targets in Advanced Melanoma. Cancers (Basel). 2021;14(1)doi: 10.3390/cancers14010081.
Ferrucci, P. F., & Cocorocchio, E. (2021). Novel Biomarkers and Druggable Targets in Advanced Melanoma. Cancers, 14(1), . https://doi.org/10.3390/cancers14010081
Ferrucci, Pier Francesco, and Cocorocchio, Emilia. "Novel Biomarkers and Druggable Targets in Advanced Melanoma." Cancers vol. 14,1 (2021). doi: https://doi.org/10.3390/cancers14010081
Ferrucci PF, Cocorocchio E. Novel Biomarkers and Druggable Targets in Advanced Melanoma. Cancers (Basel). 2021 Dec 24;14(1). doi: 10.3390/cancers14010081. PMID: 35008245; PMCID: PMC8750474.
Copy Download .nbib Format: NLM
Sex-Based Dimorphism of Anticancer Immune Response and Molecular Mechanisms of Immune Evasion.

Clinical cancer research : an official journal of the American Association for Cancer Research

Conforti F, Pala L, Pagan E, Bagnardi V, De Pas T, Queirolo P, Pennacchioli E, Catania C, Cocorocchio E, Ferrucci PF, Saponara M, Orsolini G, Zagami P, Nicoló E, De Marinis F, Tortora G, Bria E, Minucci S, Joffe H, Veronesi P, Wargo J, Rosenthal R, Swanton C, Mantovani A, Gelber RD, Viale G, Goldhirsch A, Giaccone G.
PMID: 34016641
Clin Cancer Res. 2021 Aug 01;27(15):4311-4324. doi: 10.1158/1078-0432.CCR-21-0136. Epub 2021 May 20.

PURPOSE: We previously demonstrated that sex influences response to immune checkpoint inhibitors. In this article, we investigate sex-based differences in the molecular mechanisms of anticancer immune response and immune evasion in patients with NSCLC.EXPERIMENTAL DESIGN: We analyzed (i) transcriptome...

Cite
Conforti F, Pala L, Pagan E, et al. Sex-Based Dimorphism of Anticancer Immune Response and Molecular Mechanisms of Immune Evasion. Clin Cancer Res. 2021;27(15):4311-4324doi: 10.1158/1078-0432.CCR-21-0136.
Conforti, F., Pala, L., Pagan, E., Bagnardi, V., De Pas, T., Queirolo, P., Pennacchioli, E., Catania, C., Cocorocchio, E., Ferrucci, P. F., Saponara, M., Orsolini, G., Zagami, P., Nicoló, E., De Marinis, F., Tortora, G., Bria, E., Minucci, S., Joffe, H., Veronesi, P., Wargo, J., Rosenthal, R., Swanton, C., Mantovani, A., Gelber, R. D., Viale, G., Goldhirsch, A., & Giaccone, G. (2021). Sex-Based Dimorphism of Anticancer Immune Response and Molecular Mechanisms of Immune Evasion. Clinical cancer research : an official journal of the American Association for Cancer Research, 27(15), 4311-4324. https://doi.org/10.1158/1078-0432.CCR-21-0136
Conforti, Fabio, et al. "Sex-Based Dimorphism of Anticancer Immune Response and Molecular Mechanisms of Immune Evasion." Clinical cancer research : an official journal of the American Association for Cancer Research vol. 27,15 (2021): 4311-4324. doi: https://doi.org/10.1158/1078-0432.CCR-21-0136
Conforti F, Pala L, Pagan E, Bagnardi V, De Pas T, Queirolo P, Pennacchioli E, Catania C, Cocorocchio E, Ferrucci PF, Saponara M, Orsolini G, Zagami P, Nicoló E, De Marinis F, Tortora G, Bria E, Minucci S, Joffe H, Veronesi P, Wargo J, Rosenthal R, Swanton C, Mantovani A, Gelber RD, Viale G, Goldhirsch A, Giaccone G. Sex-Based Dimorphism of Anticancer Immune Response and Molecular Mechanisms of Immune Evasion. Clin Cancer Res. 2021 Aug 01;27(15):4311-4324. doi: 10.1158/1078-0432.CCR-21-0136. Epub 2021 May 20. PMID: 34016641; PMCID: PMC7611463.
Copy Download .nbib Format: NLM
Dabrafenib in metastatic melanoma: a monocentric 'real life' experience.

Ecancermedicalscience

Cocorocchio E, Gandini S, Alfieri S, Battaglia A, Pennacchioli E, Tosti G, Spadola G, Barberis M, Leo MD, Riviello C, Pala L, Intelisano A, Martinoli C, Ferrucci PF.
PMID: 26981153
Ecancermedicalscience. 2016 Mar 03;10:624. doi: 10.3332/ecancer.2016.624. eCollection 2016.

Dabrafenib is a potent BRAF-kinase inhibitor. Its activity was evaluated on 40 consecutive metastatic melanoma patients (pts) harboring the V600BRAF mutations. Dabrafenib was administered orally at the dosage of 150 mg b.i.d. daily. ORR was 82%, with 7% CR,...

Cite
Cocorocchio E, Gandini S, Alfieri S, et al. Dabrafenib in metastatic melanoma: a monocentric 'real life' experience. Ecancermedicalscience. 2016;10:624doi: 10.3332/ecancer.2016.624.
Cocorocchio, E., Gandini, S., Alfieri, S., Battaglia, A., Pennacchioli, E., Tosti, G., Spadola, G., Barberis, M., Leo, M. D., Riviello, C., Pala, L., Intelisano, A., Martinoli, C., & Ferrucci, P. F. (2016). Dabrafenib in metastatic melanoma: a monocentric 'real life' experience. Ecancermedicalscience, 10624. https://doi.org/10.3332/ecancer.2016.624
Cocorocchio, E, et al. "Dabrafenib in metastatic melanoma: a monocentric 'real life' experience." Ecancermedicalscience vol. 10 (2016): 624. doi: https://doi.org/10.3332/ecancer.2016.624
Cocorocchio E, Gandini S, Alfieri S, Battaglia A, Pennacchioli E, Tosti G, Spadola G, Barberis M, Leo MD, Riviello C, Pala L, Intelisano A, Martinoli C, Ferrucci PF. Dabrafenib in metastatic melanoma: a monocentric 'real life' experience. Ecancermedicalscience. 2016 Mar 03;10:624. doi: 10.3332/ecancer.2016.624. eCollection 2016. PMID: 26981153; PMCID: PMC4778691.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 18 entries